IDXX vs TRIB
Idexx Laboratories Inc. and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | IDXX | TRIB |
|---|---|---|
| Revenue | $4.3B | $61.6M |
| Net income | $1.1B | $-31.8M |
| Gross margin | 61.8% | 34.8% |
| Net margin | 24.6% | −50.7% |
| Return on equity | 66.2% | · |
| Diluted EPS | $13.08 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $1.1B | $-4.6M |
| Equity | $1.6B | · |
| Net debt / equity | 0.17× | · |
| Current ratio | 1.23× | 1.28× |
| Revenue CAGR 5y | 9.7% | −7.4% |
| Profit CAGR 5y | 12.7% | · |
IDXX bills 69.9× the revenue of TRIB, and TRIB closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | IDXX | TRIB |
|---|---|---|
| FY2024 | $3.9B | $61.6M |
| FY2023 | $3.7B | $56.8M |
| FY2022 | $3.4B | $62.5M |
| FY2021 | $3.2B | $81.1M |
| FY2020 | $2.7B | $102.0M |
| FY2019 | $2.4B | $90.4M |
| FY2018 | $2.2B | $97.0M |
| FY2017 | $2.0B | $99.1M |
| FY2016 | $1.8B | $99.6M |
| FY2015 | $1.6B | $100.2M |
Bottom line
| Fiscal year | IDXX | TRIB |
|---|---|---|
| FY2024 | $887.9M | $-31.8M |
| FY2023 | $845.0M | $-24.0M |
| FY2022 | $679.1M | $-41.0M |
| FY2021 | $744.8M | $875,000 |
| FY2020 | $581.8M | $-6.4M |
| FY2019 | $427.7M | $-28.9M |
| FY2018 | $377.0M | $-22.1M |
| FY2017 | $263.1M | $-40.3M |
| FY2016 | $222.0M | $-100.6M |
| FY2015 | $192.1M | $21.8M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +$3,835,949,000 | IDXX |
| FY2023 | +$3,604,121,000 | IDXX |
| FY2022 | +$3,304,803,000 | IDXX |
| FY2021 | +$3,134,211,000 | IDXX |
| FY2020 | +$2,604,675,000 | IDXX |
| FY2019 | +$2,316,473,000 | IDXX |
| FY2018 | +$2,116,207,000 | IDXX |
| FY2017 | +$1,869,918,000 | IDXX |
| FY2016 | +$1,675,812,000 | IDXX |
| FY2015 | +$1,501,697,000 | IDXX |
IDXX has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +73.5 pp | IDXX |
| FY2023 | +88.0 pp | IDXX |
| FY2022 | +89.9 pp | IDXX |
| FY2021 | +25.4 pp | IDXX |
| FY2020 | +27.4 pp | IDXX |
| FY2019 | +49.8 pp | IDXX |
| FY2018 | +40.4 pp | IDXX |
| FY2017 | +52.4 pp | IDXX |
| FY2016 | +51.2 pp | IDXX |
| FY2015 | −10.1 pp | TRIB |
The higher net margin has changed hands between IDXX and TRIB over this period.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRIB's net margin has been more volatile than IDXX's over the 10 comparable fiscal years — 27.4 percentage points of standard deviation against 4.2.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between IDXX and TRIB over these 10 fiscal years — IDXX led in 9 and TRIB in 1.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.